SCHEMBL24599481

SCHEMBL24599481

BC(=O)Nc1ncc(C(CCCCC)CCCCCC)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 10/20 0.47
PSEN2 P49810 10/20 0.47
APH1B Q8WW43 10/20 0.47
NCSTN Q92542 10/20 0.47
APH1A Q96BI3 10/20 0.47
PSENEN Q9NZ42 10/20 0.47
CCNE1 P24864 6/20 0.43
CDK2 P24941 6/20 0.43
CDK5 Q00535 6/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
MAPK10 P53779 1/20 0.42
LMNA P02545 1/20 0.39
CCNT1 O60563 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
CCND1 P24385 1/20 0.39
CDK7 P50613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24624620 0.75 CDK2 (0.71) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL22758634 0.75 NR1I2 (0.33) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18948474 0.75 NR1I2 (0.33) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13535383 0.68 ALDH1A1 (0.38) SMN1; SMN2LMNAALDH1A1
SCHEMBL5712462 0.67 PSEN1 (0.64) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8370472 0.64 NR1I2 (0.41) LMNA
SCHEMBL25488041 0.64 HCAR2 (0.44) ALDH1A1
SCHEMBL18948422 0.64 HCAR2 (0.44) ALDH1A1
SCHEMBL21946582 0.63 NR1I2 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL24608829 0.62 GPR84 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227446-A9 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-07-20 US disclosed
US-20220213096-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO LTD (CN) 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227446-A9 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PI4KB, PI4KA, PIK3CD PSEN1 3482/4885PSEN2 3211/4885APH1B 1613/4885
US-20220213096-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PI4KB, PI4KA, PIK3CD PSEN1 3482/4885PSEN2 3211/4885APH1B 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.